Filtered By:
Condition: ALS
Management: Funding
This page shows you your search results in order of date.
Order by Relevance | Date
Total 8 results found since Jan 2013.
Long Covid is a ‘national crisis.’ So why are grants taking so long to get?
Some content has been removed for formatting reasons. Please view the original article for the best reading experience.
David Putrino, a neurophysiologist at the Icahn School of Medicine at Mount Sinai, labored through his holiday last Christmas to write a grant application for urgently needed Long Covid research. With colleagues, he hoped to tap into $1.15 billion in funding that Congress granted the National Institutes of Health (NIH) in 2020, as Long Covid emerged as a major public health problem. NIH had solicited grant applications in December 2021, just weeks before their January due date. The agency said it pla...
Source: Science of Aging Knowledge Environment - June 10, 2022 Category: Geriatrics Source Type: research
The Promoter Regions of Intellectual Disability-Associated Genes Are Uniquely Enriched in LTR Sequences of the MER41 Primate-Specific Endogenous Retrovirus: An Evolutionary Connection Between Immunity and Cognition
Discussion
We have found that, in the human genome, the promoter regions of ID-associated genes are uniquely enriched in MER41 LTRs. More specifically, nine ID-associated genes that are putatively important in cognitive evolution exhibit MER41 LTRs in their promoter regions. As more than 100 families of HERV are integrated into our genome, it was important to determine whether our findings are specific to MER41 and to ID-associated genes, and if so to what extent. Among the 133 families of HERV explored here, MER41 is the only family whose LTRs were found with statistically high frequency in the promoter regions of ID-ass...
Source: Frontiers in Genetics - April 11, 2019 Category: Genetics & Stem Cells Source Type: research
New funding to UC Riverside to significantly boost cancer, ALS research
(University of California - Riverside) Maurizio Pellecchia at the University of California, Riverside has received two grants to continue his research aimed at finding therapeutics for cancer, amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases. The first grant from the US-Egypt Science and Technology Joint Fund of the National Academy of Sciences, Engineering, and Medicine totals $190,000 for two years. The second is a nearly $2.3 million, five-year grant from the National Institute of Neurological Disorders and Stroke.
Source: EurekAlert! - Cancer - June 21, 2018 Category: Cancer & Oncology Source Type: news
Neuroscience is the Next Oncology
by Michael D. Ehlers, MD, PhD
Dr. Ehlers is with Biogen in Cambridge, Massachusetts.
Innov Clin Neurosci. 2018;15(3–4):15–16
Funding: No funding was received for the preparation of this article.
Disclosures: Dr. Ehlers is an employee and shareholder at Biogen Inc. in Cambridge, Massachusetts.
Prominent and expensive failures in Alzheimer’s disease therapies have led to a contagious belief system in some parts of the biopharma industry that neuroscience is just too hard, too risky, and too uncertain. But, might this belief system itself be a residual bias of the past? Close inspection reveals all the signs of a coming...
Source: Innovations in Clinical Neuroscience - April 1, 2018 Category: Neuroscience Authors: ICNS Online Editor Tags: Commentary Current Issue Source Type: research
Tau Imaging Among Breakthroughs Advancing the Fight against Alzheimer ' s
Worldwide, nearly44 million people now have Alzheimer ' s disease (AD) or related dementia, making these conditions the top cause of disabilities in later life. The biopharma industry has invested billions of dollars into research to treat and prevent AD1, yet this work has faced many obstacles, including difficulty identifying biomarkers, tracking the disease ’s progress in the brain, and recruiting patients to trials while they are still asymptomatic. But in recent years, we’ve begun to see breakthroughs that is driving our research in new directions. Many of these accomplishments were highlighted at the Alzh...
Source: EyeForPharma - September 21, 2016 Category: Pharmaceuticals Authors: Olga Uspenskaya-Cadoz Source Type: news
How The Ice Bucket Challenge Has Changed ALS Research
Last summer was full of people dumping buckets of ice on their heads in the name of funding ALS research. A year later, it looks like it was totally worth it.
The Ice Bucket Challenge raised over $100 million, according to the ALS Association, which is huge when you compare it to the $2.8 million it raised during the same period of the previous year.
And it turns out that this funding has already led to some exciting advances and discoveries in just a year -- a very short period of time in the field of medical research. During a Reddit AMA, researcher Jonathan Ling opened up about how helpful the Ice Bucket Cha...
Source: Science - The Huffington Post - August 12, 2015 Category: Science Source Type: news
UCLA researchers identify molecular ‘switch’ that causes Huntington’s disease–like symptoms in mice
This study makes clear that a major neuroprotective function of N17 is to prevent the mutant protein from entering the nucleus and eliciting more severe toxicities,” Yang said, adding that the result is consistent with findings from several studies of other, related disorders in which mutant proteins with expanded glutamine in the nucleus are key for jump-starting a disease.
The researchers also found that the mice in the study experienced inflammation in the brain somewhat similar to that found in people with Huntington’s.
“Neuroinflammation is emerging as a potentially shared mechanism in multiple neurodegenerative...
Source: UCLA Newsroom: Health Sciences - February 13, 2015 Category: Universities & Medical Training Source Type: news
Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial
This study is registered with ClinicalTrials.gov, number NCT00349622. Findings Stage 3 included 66 participants from stages 1 and 2 and 448 new participants. In total, 340 participants were randomly allocated to ceftriaxone and 173 to placebo. During stages 1 and 2, mean ALSFRS-R declined more slowly in participants who received 4 g ceftriaxone than in those on placebo (difference 0·51 units per month, 95% CI 0·02 to 1·00; p=0·0416), but in stage 3 functional decline between the treatment groups did not differ (0·09, −0·06 to 0·24; p=0·2370). No significant differences in survival between the groups were recorde...
Source: The Lancet Neurology - October 17, 2014 Category: Neurology Source Type: research
